B. Braun US Pharmaceutical Manufacturing LLC – FDA 483, Nov 5, 2021
B. Braun Medical Inc., a sterile drug manufacturer in Daytona Beach, FL, received a Form 483 with four observations. The inspection revealed significant issues including inadequate CAPA procedures, failure to control microbial contamination in the Water for Injection system, unvalidated reprocessing steps for IV bags, and non-adherence to visual inspection procedures and qualification requirements. These findings indicate a moderate level of severity regarding quality system deficiencies and potential product integrity risks.
ID · 2acd4053-df37-42e3-b3b4-59fc224d6a80
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.